tirzepatide europe approval FDA confirms shortage is still over, gives compounders a grace period FDA Approves Tirzepatide, A Potential

However, we did not observe significant differences in circulating IGF-1 levels with mAb treatment in older mice, though levels tended to be higher in mAb-treated females, but glucose homeostasis was not adversely affected in either sex, suggesting minimal disruption of the somatotropic axis in this older cohort of mice

The authors noted, ...semaglutide was superior to placebo for MACE reduction at all levels of baseline weight or waist circumference from early in the study. Here is a gift link to a New York Times article about this study

The Ceres PR Team Changing UK food culture Talk about punching above your weight

ACS Mater Au

Eur J Drug Metab Pharmacokinet 1991, 3648 Frolich J, Seccombe DW, Hahn P, et al